FibroGen (FGEN)
NASDAQ:FGEN

FibroGen Stock Analysis & Ratings

FGEN Stock Chart & Stats

Day’s Range$8.63 - $9.265
52-Week Range$7.81 - $30.12
Previous Close$8.66
Volume617.18K
Average Volume (3M)915.29K
Market Cap$861.14M
P/E Ratio-2.8
Beta0.90
Next EarningsAug 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)-3.04


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

FGEN FAQ

What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $7.81 and its highest was $30.12 in the past 12 months.
    What is FibroGen’s market cap?
    FibroGen’s market cap is $861.14M.
      What is FibroGen’s price target?
      The average price target for FibroGen is $8.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.00 ,the lowest forecast is $8.00. The average price target represents -7.91% Decrease from the current price of $9.23.
        What do analysts say about FibroGen?
        FibroGen’s analyst rating consensus is a ‘Moderate Sell. This is based on the ratings of 2 Wall Streets Analysts.
          When is FibroGen’s upcoming earnings report date?
          FibroGen’s upcoming earnings report date is Aug 08, 2022 which is in 74 days.
            How were FibroGen’s earnings last quarter?
            FibroGen released its earnings results on May 09, 2022. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.832 by $0.152.
              Is FibroGen overvalued?
              According to Wall Street analysts FibroGen’s price is currently Overvalued.
                Does FibroGen pay dividends?
                FibroGen does not currently pay dividends.
                What is FibroGen’s EPS estimate?
                FibroGen’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does FibroGen have?
                FibroGen has 93,300,000 shares outstanding.
                  What happened to FibroGen’s price movement after its last earnings report?
                  FibroGen reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.832. Following the earnings report the stock price went up 25.819%.
                    Which hedge fund is a major shareholder of FibroGen?
                    Among the largest hedge funds holding FibroGen’s share is PRIMECAP Management Co. It holds FibroGen’s shares valued at 160M.

                      ---

                      FibroGen Stock Analysis

                      Smart Score
                      1
                      Underperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $8.50
                      ▼(-7.91% Downside)
                      Moderate Sell
                      The FibroGen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      FibroGen

                      FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Akebia Therapeutics
                      Affymax
                      Bristol Myers
                      AstraZeneca
                      Ardelyx

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis